Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-33.60% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
TBPH · Jun 30, 2026
Theravance Biopharma, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001104659-26-093773General Corporate
Evidence method
Yoy · gp.fundamentals.revenue
-20.86% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.operating_margin
-39.93% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
22.73% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
28.89% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History5 statesHistory building
Period transition
What moved in the state?
- Previous
- 414.03%
- Current
- -33.60%
- Delta
- -447.63%
- Previous
- 15.02%
- Current
- -20.86%
- Delta
- -35.88%
- Previous
- -53.58%
- Current
- -39.93%
- Delta
- 13.65%
- Previous
- 32.93%
- Current
- 22.73%
- Delta
- -10.20%
- Previous
- 25.45%
- Current
- 28.89%
- Delta
- 3.45%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Compared To · Pharmaceutical Preparations peers →Has State · Theravance Biopharma, Inc. →Transitioned To · TBPH Fundamental State →Transitioned To · TBPH CASH_GENERATION_DECREASED →Transitioned To · TBPH GROWTH_DECREASED →Transitioned To · TBPH PROFITABILITY_INCREASED →Transitioned To · TBPH R_AND_D_INTENSITY_DECREASED →Transitioned To · TBPH SBC_INTENSITY_INCREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.